• Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program INTUVAX®

    Learn more

Immunicum is listed on NASDAQ OMX First North Premier under the ticker IMMU.

About us

Developing innovative cancer immunotherapies

We are on a journey towards the world’s first patient unique, off-the-shelf cancer treatment. Get to know the technology that will take us there.

Learn more